Atumelnant

N/A

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NameAtumelnant
Drug Alias NameCRN-04894
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMelanocortin receptor 2 antagonists
TargetsMelanocortin receptor 2
Therapy Area/IndicationsCushing SyndromeAdrenal Hyperplasia, CongenitalPituitary ACTH Hypersecretion +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrinetics Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesQuotient Sciences LtdCrinetics Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCushing SyndromeAdrenal Hyperplasia, CongenitalPituitary ACTH Hypersecretion +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A